



1646
PATENT
Customer No. 22,852
Attorney Docket No. 4853.0085

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
OGATA et al.) Group Art Unit: 1646
)
Application No.: 10/019,501) Examiner: Not Yet Assigned
)
PCT Filing Date: July 3, 2000)
)
§ 371 Date: December 31, 2001)
)
For: AGENT FOR AMELIORATING)
LOW VASOPRESSIN LEVEL)

Commissioner for Patents
Washington, DC 20231

Sir:

RECEIVED
OCT 15 2002
TECH CENTER 1600/2900

TRANSMITTAL LETTER

Prior to the examination of the above application, the following items checked below are appropriate:

The claims are calculated below:

	Claims Remaining After Amendment		Highest Number Previously Paid	Present Extra	Rate	Additional Fee
Total	28	-	19	9	x \$ 18	\$ 162.00
Indep.	5	-	4	1	x \$ 84	84.00
<input type="checkbox"/> First Presentation of Multiple Dep. Claim(s)					+\$280	
Subtotal						\$ 246.00
Reduction by ½ if small entity						-
TOTAL						\$ 246.00

■ A fee of \$ 246.00 to cover the cost of the additional claims is enclosed.

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Dated: October 9, 2002

By: Rebecca M. McNeill
Rebecca M. McNeill
Reg. No. 43,796

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com



PATENT

Customer No. 22,852

Attorney Docket No. 4853.0085-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

OGATA et al.

Application No.: 10/019,501

PCT Filing Date: July 3, 2000

§371 Date: December 31, 2001

For: AGENT FOR AMELIORATING
LOW VASOPRESSIN LEVEL

)

)

) Group Art Unit: 1646

)

) Examiner: Not yet assigned

)

)

)

)

)

)

)

Commissioner for Patents
Washington, DC 20231

Sir:

SUPPLEMENTAL PRELIMINARY AMENDMENT

Prior to the examination of the above application, please amend this application
as follows:

IN THE CLAIMS:

Please amend claims 1-15, as follows:

1. (Twice Amended) A method of maintaining or increasing low vasopressin
level comprising administering to a patient at least one substance that inhibits the
binding between PTHrP and a receptor thereof, allowing the substance to inhibit the
binding of PTHrP and its receptor, and maintaining or increasing vasopressin level.
2. (Twice Amended) The method according to claim 1, wherein the
substance is an antagonist against a PTHrP receptor.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

10/10/2002 TBESHAM 00000086 10019501

01 FC:103
02 FC:102

162.00 OP
84.00 OP

RECEIVED
OCT 15 2002
TECH CENTER 1600/2900